VolitionRx Limited (VNRX) Signs LOI to Develop NETosis Lateral Flow Test

VolitionRx (VNRX) signed a non-binding LOI with Missionpharma to develop, manufacture, and distribute a lateral flow test for NETosis, targeting decentralized use. The test aims at applications in low- and middle-income countries and neonatal sepsis triage.

Original reporting
Published Oct 27, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
VolitionRx Limited (VNRX) Signs LOI to Develop NETosis Lateral Flow Test — source image
Decision brief

The 30-second read

Low
01

Why it matters

The LOI signals early partnership but lacks binding commitments, limiting immediate market impact.

02

Market read

Early-stage partnership with modest immediate relevance; may affect niche biotech investors.

03

What to watch

absence of binding terms, regulatory approvals, and purchase commitments

Relevance 5/10Novelty 5/10Timing: immediate

Background

VolitionRx is a biotech company developing a NETosis lateral flow test for sepsis triage.

Market effects

potential interest in NETosis diagnostics within biotech sector

limited to Australian biotech market

minimal

Counterpoint

LOI may not lead to commercial product; risk of delay or termination

Key entities

  • VolitionRx Limited

    Biotech firm developing NETosis test

  • Missionpharma

    Partner for development and distribution

Related articles

$VNRXMed

VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, November 12, 2026 /PRNewswire/ -- Vo

$VNRXMedAI 8/10

Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

$VNRXLow

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

$VNRXMed

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

$NVDAHigh

Who could replace the departed Jensen Huang as Nvidia CEO?

Nvidia's CEO Jensen Huang resigned following allegations of extramarital affairs. Colette Kress, the CFO, is named interim CEO. Potential successors include Ian Buck and Rene Haas. Nvidia, with a $4tn market cap, is a key player in AI and the US economy. Kress has been with Nvidia since 2013 and has overseen its growth into an AI leader.